Recruiting Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN NCT07498335 Conditions Autoimmune Diseases, Berger Disease, Bergers Disease, +20 more Locations Hackensack Meridian Health — Neptune City, New Jersey, United States Cincinnati Childrens Hospital MC — Cincinnati, Ohio, United States University of Oklahoma Health Science Center — Oklahoma City, Oklahoma, United States University of Tennessee Health Science Center- Le Bonheur Research Center — Memphis, Tennessee, United States View more locations Show fewer locations Loading locations... View Trial Details
Enrolling by Invitation A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept NCT06674577 Conditions Autoimmune Diseases, Berger Disease, Female Urogenital Diseases, +11 more Locations Vera Therapeutics — Brisbane, California, United States View Trial Details
Active, Not Recruiting Monthly Dosing of Atacicept in IgAN NCT07020923 Conditions Autoimmune Diseases, Berger Disease, Female Urogenital Diseases, +10 more Locations Vera Therapeutics — Brisbane, California, United States View Trial Details
Active, Not Recruiting Atacicept in Subjects With IgA Nephropathy NCT04716231 Conditions Autoimmune Diseases, Berger Disease, Female Urogenital Diseases, +10 more Locations ORIGIN 3 Global Site Contact Information — Brisbane, California, United States View Trial Details
